Perspectum Announces World’s 1st Integrated Imaging Service for Long Covid Is Approved by UK’s MHRA

January 14, 2021

The UK’s Medicines & Healthcare products Regulatory Agency (MHRA) approved the use of CoverScan MD, an MRI-based technology that maps the effects of COVID-19 on several of the body’s key organs, developed by Perspectum. With 1 in 20 COVID-19 patients predicted to experience ongoing symptoms, or “Long COVID”, CoverScan MD quickly and safely provides medical professionals with the information critically needed to assess and evaluate patients.

“I’m thrilled to hear that Coverscan** has been granted approval by MHRA. I cannot stress enough how much myself and a large number of people with Long Covid* have benefitted from Coverscan. For those of us with organ damage, it has accelerated our access to treatment by informing us exactly what organs need to be examined further, while for the rest of us, it has brought us invaluable peace of mind. This is a step in the right direction, and I hope everyone who is misfortunate enough to suffer from Long Covid can benefit from this.”

Lyth Hishmeh, COVERSCAN Study Patient

‘The MHRA authorization of Coverscan is timely. UK experts and NICE are developing a COVID follow up a pathway which provides equitable access and high-quality community-based triage with rapid access to diagnostics and multi-specialty services. We have seen over 800 patients in North London, and it would be very valuable for their clinical care to be able to access COVERSCAN results.’

Dr. Melissa Heightman, Consultant Respiratory Physician, UCL, and Head of North London Long Covid care services

Perspectum’s CoverScan MD technology enables healthcare providers to identify coronavirus-related systemic organ damage through scans of patients’ hearts, lungs, livers, as well as other internal organs, and to assess the impact of SARS-CoV-2 infections. With the use of CoverScan MD, UK doctors will now have a technology to add to the arsenal of tools used to assess and evaluate patients with Long COVID, while at the same time gain a greater understanding of its symptoms and long-term impact on different organ systems.

*Long Covid affects 10-30% of people who have symptomatic infection with Sars-CoV-2 and is defined as symptomatic disease lasting longer than 12 weeks. Patients typically have extreme fatigue, chest pain, breathlessness, muscle aches, and brain fog, but there are many reported symptoms. Many of these patients have organ damage or impairment, and ways of managing this are currently being researched. Patients with Long Covid are often unable to work for long periods of time, posing a significant burden on the economy and public services.

**CoverScan MD is a software suite that provides a comprehensive, one-stop-shop assessment to detect damage in the heart, liver, lungs, kidneys, pancreas, and spleen. This single, quick MRI exam eliminates the need for multiple individual or invasive tests.

Healthcare professionals and patients are then provided with quantitative measurements and accurate information, enabling them to develop personalized treatment plans for the long-term care of patients. MHRA authorization will allow this technology to be made available to UK patients.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

New supply contract to bring Lunit INSIGHT CXR to TeleDiag in France and Lunit INSIGHT MMG to the Central region branch of the Portuguese League Against Cancer
KA Imaging reported a collection of positive metrics to its stakeholders, with revenue four times larger than that of the previous year and a 38% growth in headcount in 2023. The positive trend continues to be observed in Q1 2024.
Isaac Zaworski, President of Sectra advises: "Collaborating across sites and providing efficient radiology workflows are needed to cope with the increasing imaging volumes. This new customer is the 60th healthcare provider to use Sectra in the US Midwest and I'm pleased to be continuing our work in this area. With our local experience as well as our knowledge in providing multi-site solutions for large organizations we will help them on this journey in the best way possible."
MediView notes the system, which has received 510(k) clearance from the U.S. Food and Drug Administration and is currently in clinical use, is intended to be used adjunctively for minimally invasive ultrasound guided needle-based procedures for soft tissue and bone.
The new CT 5300 system is already installed at several European hospitals and has been well-received. “CT 5300 offers CT imaging from head to toe, combined with high-end functionality such as coronary angiography, delivering an extremely broad spectrum of applications, helping us to better manage increased volumes of patients,” said Dr. Hilmar Kühl, Head of Radiology at St. Bernhard-Hospital Kamp-Lintfort, Germany. “With this latest system from Philips, we see an improvement in image quality with Precise Imaging, and for the first time, we can now visualize cardiac anatomy by using Precise Cardiac nearly artifact-free, which is very valuable to help improve cardiac care for our patients.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy